JCR Pharmaceuticals Co., Ltd. (4552.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
JCR Pharmaceuticals Co., Ltd.
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
985
First IPO Date
November 17, 2005
Key Executives
| Name | Title | Pay | Year Born |
| Anne Bechet | Managing Exec Officer, Exec Direc of Development Div., JCR Europe B.V. GM & JCR USA Inc. CEO | 0 | N/A |
| Andrea Spezzi FFPM | Senior Managing Executive Officer of Development Division & Director | 143M | 1965 |
| Katsuya Nishino | Executive Vice President | 0 | 1956 |
| Makoto Ashida | Managing Executive Officer & Executive Director of Production Division | 0 | N/A |
| Yoh Ito | Managing Executive Officer & Executive Director of Corporate Strategy Division | 0 | N/A |
| Tomohiko Miyagawa | Executive Officer and Executive Director of Sales Division | 0 | N/A |
| Takafumi Shimizu | Director of Marketing Dept. & Sales Division | 0 | N/A |
| Toshiaki Ikeda | Group Leader of the Clinical Development Group - International Development | 0 | N/A |
| Yutaka Honda | Senior Managing Executive Officer, Exec Director of Administration Div. & Head of Exec Office | 0 | N/A |
| Hiroyuki Fukuya | Exec Off, Dir of Legal & Compliance, Internal Control Dept and Chief Legal & Compliance Off | 0 | N/A |
| Hiroyuki Sonoda | President, Chief Scientific Officer & Representative Director | 0 | 1978 |
| Shin Ashida | Founder & Director | 0 | 1943 |
| Yoshihiro Ota | Director of Accounting Department & Corporate Strategy Department (Finance) | 0 | N/A |
| Hiroshi Yoshimoto | Senior Advisor | 0 | 1951 |
| Shinji Okamoto | Director of Human Resources Department & Administration Division | 0 | N/A |
Description
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
